ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 242780" data-attributes="member: 13851"><p><strong>Figure 1 (a) <u>Basic domain arrangement of phosphodiesterase 5 (PDE5) enzyme with three identified PDE5 isoforms (i.e., PDE5A1, PDE5A2, PDE5A3)</u>. Note that the key features of PDEs include the conserved carboxy-terminal end and a variable regulatory amino-terminal domain. The regulatory region of PDE5 contains two GAF domains (GAF-A and GAF-B) that control catalytic activity and dimerization of the protein. The binding of cyclic guanosine monophosphate (cGMP) to the GAF-A nucleotide pocket allosterically modulates the catalytic activity, while the C-terminal GAF-B domain plays a role in the dimerization of the PDE5 enzyme. (b) <u>Chemical structures of the commonly used inhibitors of PDE5, which include those administered in humans as the US Food and Drug Administration–approved therapies for the management of erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract symptoms</u>. Compounds 1–9 are newly synthesized compounds for potential therapeutic use for neurodegenerative diseases. Compounds 1, 3, and 5–9 adapted with permission from Reference 182. CM-414 adapted with permission from Reference 199.</strong></p><p><strong>[ATTACH=full]28303[/ATTACH]</strong></p><p><strong>[ATTACH=full]28304[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 242780, member: 13851"] [B]Figure 1 (a) [U]Basic domain arrangement of phosphodiesterase 5 (PDE5) enzyme with three identified PDE5 isoforms (i.e., PDE5A1, PDE5A2, PDE5A3)[/U]. Note that the key features of PDEs include the conserved carboxy-terminal end and a variable regulatory amino-terminal domain. The regulatory region of PDE5 contains two GAF domains (GAF-A and GAF-B) that control catalytic activity and dimerization of the protein. The binding of cyclic guanosine monophosphate (cGMP) to the GAF-A nucleotide pocket allosterically modulates the catalytic activity, while the C-terminal GAF-B domain plays a role in the dimerization of the PDE5 enzyme. (b) [U]Chemical structures of the commonly used inhibitors of PDE5, which include those administered in humans as the US Food and Drug Administration–approved therapies for the management of erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract symptoms[/U]. Compounds 1–9 are newly synthesized compounds for potential therapeutic use for neurodegenerative diseases. Compounds 1, 3, and 5–9 adapted with permission from Reference 182. CM-414 adapted with permission from Reference 199. [ATTACH type="full"]28303[/ATTACH] [ATTACH type="full"]28304[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top